IMPORTANT SAFETY INFORMATION

Warnings and Precautions<ul><li>Gallbladder abnormalities may occur. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, and pancreatitis, which required cholecystectomy in patients taking Sandostatin LAR Depot. Patients should be monitored periodically. If complications of cholelithiasis are suspected, discontinue Sandostatin LAR Depot and treat appropriately</li><li>Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should be monitored when Sandostatin LAR Depot treatment is initiated or when the dose is altered. Antidiabetic treatment should be adjusted accordingly</li><li>Thyroid Function: Hypothyroidism may occur. Baseline and periodic assessment of thyroid function (TSH, total and/or free T4) is recommended</li><li>Cardiac Function: Bradycardia, arrhythmia, conduction abnormalities, and other electrocardiogram changes may occur. The relationship of these events to octreotide acetate is not established because many of these patients have underlying cardiac disease. Use with caution in at-risk patients</li><li>Steatorrhea and Malabsorption of Dietary Fats: New-onset steatorrhea, stool discoloration, and loose stools have been reported. Octreotide may alter absorption of dietary fats and subsequent symptoms of steatorrhea, loose stools, abdominal bloating, and weight loss. If new occurrence or worsening symptoms are reported, evaluate patients for potential pancreatic exocrine insufficiency and manage accordingly</li><li>Changes in Vitamin B12 and Zinc Levels: Monitoring of vitamin B12 levels is recommended during therapy with Sandostatin LAR Depot. Patients on total parenteral nutrition and octreotide should have periodic monitoring of zinc levels</li></ul>Drug Interactions<ul><li>The following drugs require monitoring and possible dose adjustment when used with Sandostatin LAR Depot: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Drugs mainly metabolized by CYP3A4, and which have a low therapeutic index, should be used with caution</li><li>Octreotide competitively binds to somatostatin receptors and may interfere with the efficacy of lutetium LU 177 dotatate. Discontinue Sandostatin LAR Depot at least 4 weeks prior to each lutetium Lu 177 dotatate dose</li></ul>Adverse ReactionsThe most common adverse reactions occurring in patients receiving Sandostatin LAR Depot were:<ul><li>Acromegaly: biliary abnormalities (52%), diarrhea (36%-48%), cholelithiasis (13%-38%), abdominal pain or discomfort (11%-29%), flatulence (26%), influenza-like symptoms (20%), constipation (19%), headache (15%), anemia (15%), hyperglycemia (15%), injection-site pain (2%-14%), hypertension (13%), dizziness (12%), fatigue (11%), nausea (10%), vomiting (7%), hypothyroidism (2%), hypoglycemia (2%), and goiter (2%)</li><li>Carcinoid Tumors and VIPomas: biliary abnormalities (62%), injection-site pain (20%-50%), nausea (24%-41%), abdominal pain (10%-35%), fatigue (8%-32%), headache (16%-30%), hyperglycemia (27%), back pain (8%-27%), constipation or vomiting (15%-21%), dizziness (18%-20%), sinus bradycardia (19%), pruritus (18%), upper respiratory tract infection (10%-18%), myalgia (4%-18%), flatulence (9%-16%), arthropathy (8%-15%), rash (15%), generalized pain (4%-15%), sinusitis (5%-12%), conduction abnormalities (9%), hypoglycemia (4%), and arrhythmia (3%)</li></ul>Please see full <a href="https://www.novartis.com/us-en/sites/novartis_us/files/sandostatin_lar.pdf" target="_blank" rel="noopener">Prescribing Information</a>.

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for:<ul><li>Long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal)</li><li>Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors</li><li>Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors</li></ul>In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

INDICATIONS AND USAGE

Warnings and Precautions<ul><li>Gallbladder abnormalities may occur. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, and pancreatitis, which required cholecystectomy in patients taking Sandostatin LAR Depot. Patients should be monitored periodically. If complications of cholelithiasis are suspected, discontinue Sandostatin LAR Depot and treat appropriately...</li></ul>

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for...

Not to worry. You can head over to our homepage or check out some of our content.

We're sorry - you do not have access.

The URL may have been incorrectly typed or the page may have been moved, deleted, or incorporated into another part of the website.

The webpage you are looking for is unavailable.

We're sorry - it looks like there is an issue

neutral_0

You are about to leave a Novartis site and continue to an external website independently operated and not managed by Novartis Pharmaceuticals Corporation.

You are about to leave SANDOSTATIN-LAR-DEPOT-HCP.com

You are now being directed to another Novartis website.

Lato

Poppins

<a href="/acromegaly">Acromegaly</a>

<a href="/carcinoid-syndrome">Carcinoid Syndrome</a>

Site Map

Home

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE